STOCK TITAN

Ainos, Inc. - AIMD STOCK NEWS

Welcome to our dedicated page for Ainos news (Ticker: AIMD), a resource for investors and traders seeking the latest updates and insights on Ainos stock.

Ainos, Inc. (NASDAQ: AIMD) is a diversified healthcare company headquartered in San Diego, California, specializing in developing innovative medical technologies for point-of-care testing (POCT), low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine. The company's flagship product is VELDONA®, a low-dose oral interferon-alpha formulation aimed at enhancing immune responses against a range of diseases. Ainos' VELDONA® has shown promise in treating human disease indications such as influenza, hepatitis C, thrombocytopenia, as well as HIV-related oral warts and Behçet's disease, both of which have received Orphan Drug Designation by the U.S. FDA.

Ainos recently announced the completion of manufacturing a GMP Clinical Batch of VELDONA® in collaboration with its contract manufacturer, Swiss Pharmaceutical Co., Ltd. (Taiwan). This milestone validates Ainos' capabilities in delivering high-quality, cost-effective therapeutics and advances the company's key programs.

In addition to human therapeutics, Ainos is making strides in animal health. The company has initiated clinical trials for a new VELDONA®-based drug aimed at treating feline chronic gingivostomatitis, a serious and chronic painful oral disease. This study builds upon VELDONA®'s extensive history in animal health, demonstrating its therapeutic potential across various animal species.

Ainos is also pioneering AI-powered POCTs through its AI Nose technology platform. The company's lead POCT candidate, Ainos Flora, is designed to be a telehealth-friendly solution for women's health and common sexually transmitted infections (STIs). Furthermore, Ainos has initiated a co-development program with Nisshinbo Micro Devices Inc. and Taiwan Inabata Sangyo Co. to create a volatile organic compound (VOC) sensing platform. This technology aims to revolutionize applications in telehealth, automotive, industrial, and environmental safety, expanding Ainos' market reach.

Financially, Ainos has secured significant growth capital, including a $9 million convertible note from an existing shareholder. This funding will propel the company's initiatives in scaling up VELDONA® and advancing its AI Nose technology.

With nearly four decades of dedication to healthcare innovation, Ainos continues to push the boundaries of medical science, striving to deliver effective, safe, and high-quality treatments for both humans and animals. Investors and stakeholders are encouraged to follow Ainos on social media platforms like X (formerly Twitter) and LinkedIn for the latest updates and developments.

Rhea-AI Summary

Ainos (NASDAQ:AIMD) has secured a Taiwan invention patent for VELDONA®, its breakthrough formulation for coronavirus treatment and prevention. The company has also filed for global patent protection under the Patent Cooperation Treaty (PCT). VELDONA® utilizes an advanced oral rapid-dissolving tablet technology that enhances immune system function and reduces the risk of coronavirus infections.

Key highlights:

  • VELDONA® shows potential in activating the immune system against various coronavirus variants and preventing new infections
  • The technology may extend to other viral diseases, including Hepatitis B, HIV, and various animal viruses
  • Ainos believes VELDONA® could become a competitive, comprehensive antiviral therapy due to its high efficacy, safety, and low side effects
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
none
-
Rhea-AI Summary

Ainos (NASDAQ: AIMD, AIMDW), a healthcare company specializing in AI-powered point-of-care testing and VELDONA low-dose interferon therapeutics, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place both in-person at the Lotte New York Palace Hotel and virtually on September 9-10, 2024.

Key highlights:

  • Ainos will conduct one-on-one meetings during the conference
  • Mr. Jack Lu, Director of Corporate Development, will deliver a live presentation on September 10, 2024, at 4 p.m.
  • The company invites shareholders and interested parties to learn about their journey towards becoming 'AI's nose' capable of digitizing smell
  • Interested attendees can register for the conference through the HCW Events website
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
conferences
-
Rhea-AI Summary

Ainos, Inc. (NASDAQ:AIMD) is making significant strides in AI-powered smell digitization technology. CEO Chun-Hsien Tsai highlighted key achievements and upcoming milestones in a shareholder letter:

1. AI Nose Technology: Ainos is developing AI-powered digital nose sensors for healthcare and smart factories.

2. Healthcare Applications: The next-gen Ainos Flora, targeting women's health and STI testing, is set for clinical trials in Q4 2024.

3. Elderly Care: Collaborating with Nisshinbo Micro Devices and Taiwan Inabata Sangyo, Ainos aims for pilot production in Q4 2024.

4. Smart Factories: AI Nose achieved 79% accuracy in identifying VOCs in semiconductor factories, with pilot production ready in Q4 2024.

5. IP Portfolio: Ainos secured exclusive licenses for 10 multi-region patents related to gas sensors and medical device technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.09%
Tags
AI
Rhea-AI Summary

Ainos (NASDAQ: AIMD) has unveiled a breakthrough in its AI Nose technology, achieving 79% accuracy in identifying 761 samples across 22 volatile organic compounds (VOCs) in Japanese semiconductor manufacturing factories. This advancement significantly enhances smart manufacturing factory automation and safety. The AI Nose can detect manufacturing process contamination, ensure health and safety, prevent fires, and optimize gas sensing with real-time feedback.

Ainos plans to integrate AI Nose into smart factory robotics systems, equipping robots with a human-like sense of smell to improve collaboration with workers and enhance safety. This development expands AI Nose's applications beyond medical uses into the industrial sector, positioning Ainos as a leader in VOC sensing technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
-
Rhea-AI Summary

Ainos Inc. (NASDAQ:AIMD) announced its participation in a fireside chat with Water Tower Research on August 22, 2024, at 10:00 a.m. ET. Jack Lu, Director of Corporate Development, will present an overview of Ainos' business model, strategic priorities, and AI Nose technology platform. The discussion will cover lead pipeline products, including the low-dose IFN-α therapeutic VELDONA, and its potential in human and animal health.

The fireside chat will also address Ainos' recent earnings and financial position. This listen-only event is open for registration, and a replay will be available on the company's investor relations website. Ainos is a diversified healthcare company focusing on AI-powered point-of-care testing (POCT) and VELDONA therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Ainos, Inc. (NASDAQ:AIMD) has secured exclusive licenses for 10 invention patents and patent applications from Taiwan Carbon Nano Technology (TCNT), its affiliate and product co-developer. The licenses, valued at approximately $5.4 million, cover gas sensors and medical devices across multiple regions including the U.S., Germany, China, Japan, and Taiwan. The all-stock licensing structure aligns TCNT's interests with Ainos shareholders while preserving cash for growth.

This strategic move is expected to strengthen Ainos' AI Nose and Point-Of-Care Testing (POCT) technologies. The company is advancing its AI Nose and POCT pipeline, including the leading volatile organic compounds (VOC) POCT candidate, Ainos Flora. Ainos is also developing a VOC sensing platform with Japanese partners and progressing on the Next-Gen Ainos Flora, which implements NVIDIA CUDA technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership AI
Rhea-AI Summary

Ainos, Inc. (NASDAQ:AIMD) has prepaid its remaining convertible note financing with Lind Global Fund II LP, totaling approximately $1.67 million. The company, focused on AI-powered point-of-care testing and low-dose interferon therapeutics, maintains a robust financial runway of over 12 months after the prepayment. Ainos has recently enrolled its first subject for VELDONA®-based animal drug in treating FCGS and is developing the next-gen Ainos Flora powered by AI Nose, implementing NVIDIA CUDA. The company's CEO, Chun-Hsien Tsai, expressed gratitude for The Lind Partners' financial support and reaffirmed Ainos' commitment to building shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.42%
Tags
none
-
Rhea-AI Summary

Ainos (NASDAQ:AIMD) reported its Q2 2024 financial results, highlighting progress in its VELDONA® animal health initiatives. The company enrolled its first subject for an FCGS clinical study, marking a shift towards drug development in animal health. Ainos raised $9 million through convertible note financing, ensuring a 12+ month financial runway. Q2 2024 saw nominal revenues and a net loss of $3,195,022. R&D expenses increased to $1,978,756, while SG&A expenses rose to $1,044,880. The company's cash position improved to $8,014,098 as of June 30, 2024. Ainos is advancing its AI Nose technology and VELDONA® human drug candidates, aiming to maximize long-term shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.42%
Tags
-
Rhea-AI Summary

Ainos (NASDAQ:AIMD) has enrolled the first subject for its Taiwanese clinical study of VELDONA®-based animal drug in treating feline chronic gingivostomatitis (FCGS). The study aims to evaluate the safety, tolerability, and efficacy of low-dose oral interferons for FCGS treatment. With 30 subjects expected to be enrolled by end-2024, the trial report is anticipated to be finalized in Q1 2025. This milestone marks a significant step in Ainos' efforts to expand VELDONA's market and develop innovative treatments for cats with FCGS. The potential market is substantial, with an estimated 5.8 to 8.3 million cats in the U.S. affected by FCGS. The global pet dental health market is projected to reach US$9.98 billion by 2030, growing at a CAGR of 6.25% from 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
Rhea-AI Summary

Ainos announces significant progress in the clinical trials of its AI Nose-powered Ainos Flora device, designed for rapid, non-invasive detection of bacterial, fungal, and common sexually transmitted infections in women. The trials, conducted at four major medical centers in Taiwan, successfully tested 75 cases, validating the AI algorithm's accuracy through real-world data incorporation and comprehensive data standardization.

Building on current trial success, Ainos aims to develop a next-gen Ainos Flora with NVIDIA CUDA, targeting Q3 for design completion and Q4 for clinical trials. The new device will feature improvements for at-home testing, addressing growing demand for decentralized healthcare solutions. The STI testing market is projected to reach $256 billion by 2028, with POCT accounting for 31%.

Ainos' ongoing innovation in AI and medical technology is supported by over 50 patents. The Ainos Flora device won the 2021 iF's Medicine/Health Design Award, highlighting its effectiveness and user-friendly design for home healthcare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.32%
Tags

FAQ

What is the current stock price of Ainos (AIMD)?

The current stock price of Ainos (AIMD) is $0.7101 as of January 29, 2025.

What is the market cap of Ainos (AIMD)?

The market cap of Ainos (AIMD) is approximately 10.3M.

What does Ainos, Inc. specialize in?

Ainos specializes in developing innovative medical technologies, including point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine.

What is VELDONA®?

VELDONA® is Ainos' low-dose oral interferon-alpha formulation designed to enhance immune responses against various diseases in humans and animals.

What recent milestones has Ainos achieved?

Ainos has completed manufacturing a GMP Clinical Batch of VELDONA® and initiated clinical trials for treating feline chronic gingivostomatitis with a new VELDONA®-based drug.

What are Ainos' key products?

Ainos' key products include VELDONA® clinical-stage human therapeutics, VELDONA® Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by the AI Nose technology platform.

Who are Ainos' strategic partners?

Ainos has strategic partnerships with Swiss Pharmaceutical Co., Ltd. for manufacturing and with Nisshinbo Micro Devices Inc. and Taiwan Inabata Sangyo Co. for developing VOC sensing technology.

What financial steps has Ainos recently taken?

Ainos has secured $9 million in growth capital through a convertible note financing to scale up its VELDONA® and AI Nose initiatives.

What is the AI Nose platform?

The AI Nose platform is Ainos' AI-powered technology for POCTs and VOC sensing, with potential applications in telehealth, automotive, industrial, and environmental safety.

What is Ainos Flora?

Ainos Flora is a telehealth-friendly point-of-care test for women's health and certain common sexually transmitted infections, powered by Ainos' AI Nose technology.

What is the significance of VELDONA® in animal health?

VELDONA® has a long history in animal health, initially approved in 1985 for treating feline leukemia and canine parvovirus, and is now being explored for treating feline chronic gingivostomatitis.

How can investors stay updated on Ainos' developments?

Investors can follow Ainos on X (formerly Twitter) and LinkedIn for the latest updates and company news.
Ainos, Inc.

Nasdaq:AIMD

AIMD Rankings

AIMD Stock Data

10.28M
4.34M
70.46%
1.34%
4.5%
Medical Devices
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO